Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 7/20 | 0.98 |
| ▸ | PTGDR | Q13258 | 18/20 | 0.86 |
| ▸ | PTGIR | P43119 | 3/20 | 0.86 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Domitroban SCHEMBL98346 | 1.00 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL710021 | 0.99 | TBXA2R (0.96) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL124474 | 0.99 | TBXA2R (0.96) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2232264 | 0.99 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL9198684 | 0.99 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL9875564 | 0.99 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL361563 | 0.99 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2923394 | 0.99 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2232269 | 0.99 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL13658118 | 0.99 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11512085-B2 | Heteroaryl compound having drug activity | SHANGHAI DUDE MEDICAL TECHNOLOGY CO., LTD (CN) | 2022-11-29 | — | — | US | disclosed |
| EP-3643716-A1 | HETEROARYL COMPOUND HAVING PHARMACEUTICAL ACTIVITY | Shanghai Dude Medical Technology Co., Ltd (CN) | 2020-04-29 | — | — | EP | disclosed |
| US-20200123156-A1 | HETEROARYL COMPOUND HAVING DRUG ACTIVITY | SHANGHAI DUDE MEDICAL TECHNOLOGY CO., LTD | 2020-04-23 | — | — | US | disclosed |
| EP-3112368-B1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2020-02-12 | — | — | EP | disclosed |
| US-9072734-B2 | Quaternary ammonium salt compounds | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| CN-102459231-B | Quaternary ammonium salt compound | TEIJIN PHARMA LTD | 2015-04-22 | — | — | CN | disclosed |
| CN-1845911-B | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO | 2012-07-04 | — | — | CN | disclosed |
| CN-102459231-A | Quaternary ammonium salt compound | TEIJIN PHARMA LTD | 2012-05-16 | — | — | CN | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| CN-1845911-A | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO (JP) | 2006-10-11 | — | — | CN | disclosed |
| CN-1578767-A | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | TBXA2R 61/4885PTGDR 1216/4885PTGIR 987/4885 |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | TBXA2R 485/4885PTGDR 123/4885PTGIR 244/4885 |
| US-20200123156-A1 | HETEROARYL COMPOUND HAVING DRUG ACTIVITY | BTK, LYN, LCK | TBXA2R 3372/4885PTGDR 4017/4885PTGIR 3958/4885 |
| US-11512085-B2 | Heteroaryl compound having drug activity | BTK, LYN, LCK | TBXA2R 3372/4885PTGDR 4017/4885PTGIR 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.